|Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function.|
|Jump to Full Text|
|PMID: 23014339 Owner: NLM Status: MEDLINE|
|Systemic antagonists of the histamine type 1 and 2 receptors (H1/2r) are widely used as anti-pruritics and central sedatives, but demonstrate only modest anti-inflammatory activity. Because many inflammatory dermatoses result from defects in cutaneous barrier function, and because keratinocytes express both Hr1 and Hr2, we hypothesized that H1/2r antagonists might be more effective if they were used topically to treat inflammatory dermatoses. Topical H1/2r antagonists additively enhanced permeability barrier homeostasis in normal mouse skin by the following mechanisms: (i) stimulation of epidermal differentiation, leading to thickened cornified envelopes; and (ii) enhanced epidermal lipid synthesis and secretion. As barrier homeostasis was enhanced to a comparable extent in mast cell-deficient mice, with no further improvement following application of topical H1/2r antagonists, H1/2r antagonists likely oppose mast cell-derived histamines. In four immunologically diverse, murine disease models, characterized by either inflammation alone (acute irritant contact dermatitis, acute allergic contact dermatitis) or by prominent barrier abnormalities (subacute allergic contact dermatitis, atopic dermatitis), topical H1/2r agonists aggravated, whereas H1/2r antagonists improved, inflammation and/or barrier function. The apparent ability of topical H1r/2r antagonists to target epidermal H1/2r could translate into increased efficacy in the treatment of inflammatory dermatoses, likely due to decreased inflammation and enhanced barrier function. These results could shift current paradigms of antihistamine utilization from a predominantly systemic to a topical approach.|
|Tzu-Kai Lin; Mao-Qiang Man; Juan-Luis Santiago; Kyungho Park; Truus Roelandt; Yuko Oda; Melanie Hupe; Debra Crumrine; Hae-Jin Lee; Maria Gschwandtner; Jacob P Thyssen; Carles Trullas; Erwin Tschachler; Kenneth R Feingold; Peter M Elias|
Related Documents :
|24691639 - Intratumoral immunization: a new paradigm for cancer therapy.
24135379 - Stearoyl-coa desaturase plays an important role in proliferation and chemoresistance in...
24715159 - Molecular biology of cholesteatoma.
23755279 - Modulation of apoptotic pathways of macrophages by surface-functionalized multi-walled ...
24999019 - Cystic fibrosis transmembrane conductance regulator (cftr) prevents apoptosis induced b...
23317509 - Revisiting immune-based therapies for aggressive follicular cell-derived thyroid cancers.
16793309 - Hantavirus cardiopulmonary syndrome: immune response and pathogenesis.
15618359 - Cross-talk between the interleukin-6 and prostaglandin e(2) signaling systems results i...
24691639 - Intratumoral immunization: a new paradigm for cancer therapy.
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. Date: 2012-09-27|
|Title: The Journal of investigative dermatology Volume: 133 ISSN: 1523-1747 ISO Abbreviation: J. Invest. Dermatol. Publication Date: 2013 Feb|
|Created Date: 2013-01-15 Completed Date: 2013-03-12 Revised Date: 2014-10-09|
Medline Journal Info:
|Nlm Unique ID: 0426720 Medline TA: J Invest Dermatol Country: United States|
|Languages: eng Pagination: 469-78 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Cell Differentiation / drug effects, immunology
Cimetidine / pharmacology
Dermatitis, Atopic / drug therapy*, immunology*
Dermatitis, Contact / drug therapy, immunology
Diphenhydramine / pharmacology
Disease Models, Animal
Epidermis / drug effects*, immunology*, metabolism
Histamine Antagonists / pharmacology*
Histamine H1 Antagonists / pharmacology
Histamine H2 Antagonists / pharmacology
Homeostasis / drug effects, immunology
Irritants / pharmacology
Lipid Metabolism / drug effects, immunology
Permeability / drug effects
|AR019098/AR/NIAMS NIH HHS; R01 AR019098/AR/NIAMS NIH HHS; T 545-B19//Austrian Science Fund FWF|
|0/Histamine Antagonists; 0/Histamine H1 Antagonists; 0/Histamine H2 Antagonists; 0/Irritants; 80061L1WGD/Cimetidine; 8GTS82S83M/Diphenhydramine|
Journal ID (nlm-journal-id): 0426720
Journal ID (pubmed-jr-id): 4839
Journal ID (nlm-ta): J Invest Dermatol
Journal ID (iso-abbrev): J. Invest. Dermatol.
nihms-submitted publication date: Day: 10 Month: 8 Year: 2012
Electronic publication date: Day: 27 Month: 9 Year: 2012
Print publication date: Month: 2 Year: 2013
pmc-release publication date: Day: 01 Month: 8 Year: 2013
Volume: 133 Issue: 2
First Page: 469 Last Page: 478
PubMed Id: 23014339
|TOPICAL ANTIHISTAMINES DISPLAY POTENT ANTI-INFLAMMATORY ACTIVITY LINKED IN PART TO ENHANCED PERMEABILITY BARRIER FUNCTION|
|Tzu-Kai Lin, M.D.12*|
|Mao-Qiang Man, M.D.1*|
|Juan-Luis Santiago, M.D.13*|
|Kyungho Park, Ph.D.1|
|Truus Roelandt, M.D.14|
|Yuko Oda, M.D.1|
|Melanie Hupe, M.S.1|
|Debra Crumrine, B.S.1|
|Hae-Jin Lee, M.D.5|
|Maria Gschwandtner, Ph.D.6|
|Jacob P. Thyssen, M.D., Ph.D.17|
|Carles Trullas, Ph.D.8|
|Erwin Tschachler, M.D., Ph.D.6|
|Kenneth R. Feingold, M.D.9|
|Peter M. Elias, M.D.1|
1Dermatology Service, Department of Veterans Affairs Medical Center, and Department of Dermatology, UCSF, San Francisco, CA, USA
2Department of Dermatology, National Cheng Kung University Hospital, and Graduate Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
3Department of Dermatology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
4Department of Dermatology, Universitair Ziekenhuis Brussel-Vrije, Universiteit Brussel, Brussels, Belgium
5Department of Dermatology, Yonsei University, Wonju College of Medicine, Wonju, Gangwon, South Korea
6Department of Dermatology, University of Vienna Medical School, Vienna, Austria
7Department of Dermato-Allergology, Copenhagen University Hospital Gentofte, Hellerup, Denmark
8ISDIN, Research & Development, Barcelona, Spain
9Medical Service, Department of Veterans Affairs Medical Center, and Department of Medicine, UCSF, San Francisco, CA, USA
|Correspondence: Corresponding Author: Peter M. Elias, MD, Dermatology Service, VA Medical Center, 4150 Clement Street, MS 190, San Francisco, CA 94121, TEL: (415) 750-2091, FAX: (415) 750-2106, email@example.com
*Each of these three authors contributed equally, and should be considered co-first authors.
Because of their common embryologic origin, epidermis not surprisingly expresses multiple neuroreceptors, neurotransmitters and neurohormones that mediate important functions in the central nervous system (Denda, 2002, Denda, et al., 2007). One of these mediators is histamine (Travis, et al., 2000), an aminergic neurotransmitter that is produced not only by neurons, but also by mast cells, eosinophils and basophils (Endo, et al., 1992, Endo, et al., 1995, Yamaguchi, et al., 2000). In contrast to the limited number of cell types that synthesize histamine, one or more of four histamine receptors (H1r-4r), belonging to the superfamily of G-protein-coupled receptors, are ubiquitous and modulate a variety of pathophysiological responses, including pruritus and inflammation in the skin (Hill, et al., 1997, Oda, et al., 2000). Yet, though systemic antihistamines are widely deployed in clinical settings, they demonstrate only modest anti-inflammatory activity in diseases such as atopic dermatitis (Klein and Clark, 1999, Diepgen, 2002, Kawashima, et al., 2003, Buddenkotte, et al., 2010, Eschler and Klein, 2010). Moreover, their utilization can be limited by important side effects, including sedation and cardiotoxicity, particularly in the elderly [rev. in (Greaves, 2005)]. The reason for the limited anti-inflammatory activity of systemic antihistamines is not known, but it seems plausible that either their bioavailability to peripheral tissues could be limited at current dosage levels, or that they could be substantially metabolized prior to their arrival in the skin. Because the H1r and H2r are strongly expressed in epidermis [(Gschwandtner, et al., 2011) and these studies], and because one prior study showed that topical H1/2r antagonists improve barrier function in normal skin (Ashida, et al., 2001), we hypothesized here that the bioavailability and efficacy of antihistamines could be enhanced, were they deployed as topical, rather than as systemic agents to treat inflammatory dermatoses, with or without associated barrier abnormalities.
Epidermis mediates a set of protective functions, including maintenance of permeability barrier homeostasis. This critical function, which allows survival in a terrestrial environment, is mediated by the unique two-compartment organization of the stratum corneum (SC) into anucleate corneocytes embedded in an expanded, lipid-enriched extracellular matrix [rev. in (Elias and Menon, 1991)]. Inflammatory dermatoses are now increasingly recognized to result from inherited abnormalities that compromise epidermal barrier function (Sandilands, et al., 2009, Irvine, et al., 2011). A likely pathogenic sequence that leads to inflammation invokes both increased allergen penetration, through a genetically-impaired barrier, leading to Th2 inflammation (Irvine, et al., 2011) and an epidermis-initiated ‘cytokine cascade’ that recruits downstream inflammation (Wood, et al., 1992, Nickoloff and Naidu, 1994). Accordingly, immune abnormalities, once seen as the primary disease instigator, are now increasingly considered as downstream or disease-modifying participants (Elias, et al., 2008a, Elias and Steinhoff, 2008). Then, inflammation once established, can further aggravate the barrier abnormality by multiple mechanisms, establishing an ‘outside-to-inside, back-to-outside’ pathogenic circle (Elias, et al., 2008a, Elias and Steinhoff, 2008, Elias and Schmuth, 2009). Accordingly, disorders such as atopic dermatitis, psoriasis, and the inherited ichthyoses are increasingly being treated with various forms of topical ‘barrier repair therapy,’ strategies that can themselves be anti-inflammatory by multiple mechanisms [rev. in (Elias and Wakefield, 2011)]. We show here that topical antihistamines could comprise effective therapy not only through enhanced anti-inflammatory activity, but also in part through their ability to improve epidermal structure and function. Since mast cell deficient mice (MCDM) displayed a comparable enhancement in barrier function, and since topical H1/2r antagonists provided no further benefits, the H1/2r antagonists likely oppose mast cell-derived histamine. Finally, the H1r and H2r antagonists markedly improved inflammation in four different inflammatory dermatoses models, characterized by either inflammation alone and/or a prominent barrier abnormality.
As recently reported by Gschwandtner, et al., (2011), we initially found that only the H1r and H2r are expressed in abundance in normal mouse epidermis (suppl. Fig. 1). We utilized the H1r and H2r antagonists, diphenhydramine and cimetidine here, because they most-potently improved barrier function among several agents tested in preliminary studies. Twice-daily topical applications of these H1/2r antagonists to intact skin produced only modest changes in basal barrier function, SC hydration, and surface pH, which all fell within the normal range (Figs. 1a-c). In contrast, when skin sites, previously-treated with H1/2r antagonists, were disrupted by sequential tape stripping, permeability barrier restoration accelerated (by ≈100%) in comparison to vehicle-treated sites (Fig. 1d). Moreover, co-applications of the H1r and H2r antagonists additively improved barrier function at two hours post-barrier disruption, but no additive or synergic effects were observed at four hours after barrier abrogation (Fig. 1d). Finally, when the H1r and H2r antagonists were applied unilaterally (vehicle alone applied to the opposing, similarly tape-stripped flank), barrier homeostasis improved only on the antagonist-treated side (not shown), indicating that the H1/2r antagonists enhance epidermal function locally, rather than after prior systemic absorption.
The putative source for endogenous histamine in the skin are cutaneous mast cells, which are present in substantial numbers in normal skin (Janssens, et al., 2005). To assess whether the H1/2r antagonists improve barrier function by opposing mast cell-derived histamine, we next compared barrier homeostasis in mast cell-deficient mice (MCDM, kitw/kitw-v) vs. age-matched, same-strain (WBB6F1), mast cell-replete mice. Although basal barrier function, hydration and surface pH did not differ in MCDM vs. wild-type mice, barrier recovery accelerated significantly (≈160%) in MCDM at 2 hrs vs. control mouse skin (Fig. 1e; p<0.002), an enhancement of barrier homeostasis that was comparable to that produced by the topical antihistamines. But, no further improvements in permeability barrier homeostasis occurred when MCDM were treated topically with either the H1r or H2r antagonist (Suppl. Fig. 2). Interestingly, barrier disruption provoked a modest, though significant increase in the density of mast cells (Suppl. Fig. 3). Together, these results show that: 1) topical H1r and H2r antagonists improve permeability barrier homeostasis in acutely-perturbed, but otherwise normal mouse skin [see also (Ashida, et al., 2001)]; 2) improvement is due to local effects, ruling out efficacy due to prior systemic absorption; 3) mast cell-derived histamine is likely the primary source of ligand opposed by the H1/2r antagonists; 4) barrier disruption stimulates proliferation of mast cells in the dermis; and 5) H1/2r antagonists improve barrier function specifically by opposing mast cell-derived histamine.
Corneocytes and extracellular lipids together mediate epidermal permeability barrier homeostasis (Elias, 2006, Feingold, 2007). To explore the mechanistic basis for enhanced permeability barrier function, we first assessed whether these agents alter epidermal proliferation after barrier disruption. In H+E stained sections, both H1r and H2r antagonists modestly stimulated epidermal hyperplasia (suppl. Fig. 4a–c), but the increase in thickness achieved statistical significance only in H2r antagonist–treated skin (suppl. Fig. 4d–g). Likewise, epidermal proliferation, assessed as the density of PCNA-positive cells in the basal layer, increased more in H2r- than in H1r-antagonist treated skin (suppl. Fig. 4h).
We next assessed whether one or both of these agents enhance expression of epidermal differentiation-related proteins. Applications of the H1/2r antagonists to intact skin enhanced expression of involucrin, loricrin, and particularly filaggrin in immunohistochemical preparations (Figs. 2a–i). Accordingly, epidermal mRNA levels, assessed by real-time quantitative PCR [rt(Q)-PCR] (see suppl. Table 1 for list of all primers used in the studies), increased after H1/2r antagonist applications (Fig. 2j). Finally, we assessed whether increased differentiation-linked protein expression translated into altered corneocyte structure. Electron microscopy demonstrated an apparent increase in the thickness of cornified envelopes in both H1r and H2r antagonist-treated epidermis (Fig. 3a-c), validated further in quantitative studies, utilizing randomized, coded micrographs (≈ 40% increase; p < 0.0001 for both H1/2r antagonists) (Fig. 3d). Together, these studies show that the H1r/H2r antagonist-induced improvements in barrier function can be attributed in part to enhanced epidermal differentiation, leading to more-robust corneocytes.
Epidermal permeability barrier function requires both the synthesis and ultimately the secretion of hydrophobic lipids from epidermal keratinocytes into the SC extracellular matrix (Feingold, 2009). Therefore, we next asked whether topical H1r and H2r antagonists enhance lipid production and/or secretion in normal epidermis. To assess the global impact of the antihistamines on lipid production, we initially compared fluorescence intensity after applications of nile red, a fluorophore that selectively depicts lipids, to frozen sections of topical H1/2r antagonist-treated normal skin. Both H1r and H2r antagonists markedly enhanced the overall lipid content of epidermis (Figs. 4a-c, arrows; H2r>H1r).
We next assessed whether topical H1/2r antagonist treatments enhance epidermal lipid synthesis. After four days of topical treatment, both the H1r and H2r antagonists significantly stimulated both epidermal non-saponifiable lipid and cholesterol synthesis, but only the H1r antagonist upregulated saponifiable lipid (i.e., fatty acid) synthesis (Fig. 4d). To assess the basis for enhanced lipid synthesis, we next compared changes in expression of several key lipid synthetic and lipid-modifying enzymes in epidermis two hrs after topical H1/2r antagonist applications. By rt(Q)-PCR, mRNA levels of HMGCoA reductase and serine palmitoyl transferase, the rate-linking enzymes of cholesterol and sphingoid base (ceramide) synthesis, respectively, increased significantly after topical H1/2r antagonist applications (Figs. 4e&f). Moreover, mRNA levels for two key enzymes that modify fatty acid structure, the α-hydroxylating enzyme, fatty acid 2-hydroylase (FA2H), and the elongation enzyme (elongation of very long-chain fatty acid-4, ELOVL4), which is required for acylceramide production, increased significantly after H1/2r antagonist applications (Figs. 4g&h). Together, these results demonstrate that both H1r and H2r antagonists stimulate epidermal lipid production by multiple pathways.
Newly-synthesized lipids are packaged into epidermal lamellar bodies, which then deposit their cargo at the stratum granulosum-SC interface. To determine whether the antihistamines stimulate lipid secretion, we next assessed changes in lamellar body formation after topical H1/2r antagonist applications to intact skin (Figs. 5a–f). While the density of lamellar bodies in the granular cell cytosol appeared to increase after treatment with the H2r antagonist, the H1r antagonist instead appeared to stimulate premature secretion of lamellar body contents between cells deep within the granular layer, a feature that was not evident following H2r antagonist applications (Figs. 5e vs. c). To determine the basis for enhanced lamellar body production, we next assessed mRNA levels of the epidermal-specific, transmembrane transporter, ABCA12, which delivers glucosylceramides into nascent lamellar bodies. Transporter mRNA levels increased significantly after H2r antagonist applications, a finding that correlated with increased lamellar body density in parallel samples (cf., Fig. 5e; increase after H1r antagonist applications did not achieve statistical significance, Fig. 5f). Finally, accelerated production, with or without premature secretion, correlated with enhanced deposition of lamellar body contents at the stratum granulosum-SC interface, a change more evident in H2r than in H1r antagonist-treated epidermis (Figs. 5b&d, open arrows). Together, these results suggest that the H1/2r antagonists also improve barrier function by stimulating lipid secretion.
The studies above demonstrate that topical H1/2r antagonists substantially enhance epidermal structure and function in otherwise normal skin by multiple mechanisms. Many inflammatory skin diseases are characterized not only by inflammation, but also by permeability barrier abnormalities. A primary barrier abnormality can induce inflammation (Elias and Schmuth, 2009, Elias, 2010); or conversely, a primary immunologic abnormality, as in HIV (Gunathilake, et al., 2010), can lead to abnormalities in barrier function that further stimulate inflammation (Elias, et al., 1997, Elias, et al., 1999, Elias and Feingold, 2001). Hence, we next asked whether topical H1/2r antagonists could have favorable effects in four different mouse models of cutaneous disease (suppl. Table 2).
Acute irritant contact dermatitis (AICD), induced by topical phorbol ester [12-O-tetradecanoylphorbol-13-acetate (TPA)] treatment, is characterized by inflammation, but barrier function remains within the range of normal, even after inflammation appears (2 hrs) (8.1 +/− 2.4 vs. 6.4 +/− 1.9 [SD]; n = 29-31; normal ≤ 10) (suppl. Table 2). A single application of either the H1r or H2r antagonist, immediately after the phorbol ester application, significantly reduced inflammation in AICD, quantitated as reductions in ear thickness (Fig. 6a). In parallel, dermal inflammation and epidermal hyperplasia, assessed in H+E sections, declined markedly (suppl. Fig. 6). In contrast, pre-treatment with H1/2r antagonists prior to TPA application did not prevent inflammation (ear thickness, 0.32+0.01 for vehicle, 0.29+0.01 for H1r antagonist, and 0.34+0.01 for H2r antagonist).
Acute allergic contact dermatitis (AACD), produced by a single hapten (oxazolone, Ox) challenge, after prior sensitization, also induces inflammation, without provoking an immediate barrier abnormality (Sheu, et al., 2002, Fowler, et al., 2003) (3.9 +/− 1.7 vs. 3.4 +/− 1.5 [SD]; n = 26–31; p<0.5). Both H1r and H2r antagonists markedly reduced histological evidence of inflammation (suppl Fig. 6), further quantified as a reduction in ear thickness in AACD (Fig. 6a). Yet, pretreatment again did not prevent development of inflammation (not shown). Together with the studies in AICD, these results demonstrate that topical H1/2r antagonists exhibit potent anti-inflammatory activity in dermatoses that lack a primary barrier abnormality.
Subacute allergic contact dermatitis (SACD), induced by repeated hapten challenges (3×), is characterized by both a substantial barrier abnormality (Fig. 6b), as well as inflammation. Treatment with both the H/2r antagonists significantly improved barrier function and decreased inflammation in the SACD model (Fig. 6b; but pretreatment with the antagonists again did not prevent the development of inflammation).
With further hapten challenges (10×), atopic dermatitis-like inflammation develops, in which a prominent barrier abnormality is currently thought to ‘drive’ downstream inflammation, characterized by a prominent th2-dominant immunophenotype (suppl. Table 2) (Elias, et al., 2008a, Elias and Steinhoff, 2008, Irvine, et al., 2011). When we applied specific H1/2r receptor agonists, both exacerbated inflammation in the AD model (suppl. Figs. 6&7). In contrast, H1r and H2r antagonists reduced inflammation (suppl. Figs. 6&7), but only the H2r antagonist significantly improved barrier function in this model (Fig. 6b). Since the H1/2r antagonists improved inflammation and barrier function only at sites of local application in both the SACD and AD models, systemic activity did not account for disease improvement. Yet again, neither antagonist exhibited preventive benefits in these models. These results show that H1/2r antagonists improve inflammation in the AD model, often with parallel improvements in barrier function.
Although histamine is a potent inflammatory mediator, whose levels increase markedly in inflammatory dermatoses [rev. in (Pavlinkova, et al., 2003, Greaves, 2005)], systemic antihistamines have proven ineffective as anti-inflammatory therapy for these disorders (Belsito, et al., 1990, Klein and Clark, 1999, Diepgen, 2002, Kawashima, et al., 2003, Buddenkotte, et al., 2010). Thus, these agents are largely deployed for their relatively-modest anti-pruritic or central sedating properties (Buddenkotte, et al., 2010, Eschler and Klein, 2010). Yet, their use for these purposes can be limited by important side effects, particularly in the elderly (Greaves, 2005). Systemic antihistamines could be minimally effective, either because of poor peripheral bioavailability, and/or metabolism to inactive compounds prior to their arrival in the skin (Levi-Schaffer and Eliashar, 2009). Although topical antihistamines are widely used as anti-pruritics (Eschler and Klein, 2010, Baumer, et al., 2011), whether the topical approach could provide further anti-inflammatory benefits has not yet been examined. After showing that H1r and H2r are highly-expressed in epidermis, we hypothesized that topical deployment of H1/H2r antagonists could provide a boost in anti-inflammatory activity, because of their greater bioavailability, and perhaps by improving barrier function. Pertinently, several inherited inflammatory dermatoses, including atopic dermatitis, inflammatory ichthyoses, and even psoriasis, are now seen as barrier-initiated (Sun, et al., 2006, Schmuth, et al., 2007, Tschachler, 2007, Elias, et al., 2008b, Chen, et al., 2009, Sandilands, et al., 2009, Elias, et al., 2010, Strange, et al., 2010). Hence, after initially determining whether and how these agents improve barrier function in normal epidermis, we then assessed their efficacy in several unrelated mouse models of inflammatory dermatoses.
We described here a marked improved barrier function following topical H1r and H2r antagonist applications to normal skin, confirming prior studies (Ashida, et al., 2001). We further demonstrated that H1r and H2r additively improved barrier function, at least at early time points. These results suggest that H1r and H2r could regulate epidermal function via different downstream mechanisms. Moreover, these agents appear to target the appropriate receptors, since H1/2r antagonist applications to mast cell deficient mice (MCDM) provided no further benefits for the barrier. Since the MCDM also demonstrated enhanced barrier function, and since topical H1/2r antagonists exert no further benefits, these results strongly suggest that mast cells must be the primary source of the ligand that is opposed by the H1/2r antagonists. Yet, these studies did not completely rule out other cell types as potential sources of histamine.
How these agents enhance epidermal structure and function is not yet known. We identified several mechanisms that account for enhanced permeability barrier in H1/2r antagonist-treated normal skin. First, acute barrier disruption increased the density of mast cells in the dermis, raising the question whether recruitment of mast cells to the skin contributes to the development of inflammation in dermatoses characterized by barrier abnormalities. But perhaps more importantly, the topical H1/2r antagonists directly impact epidermal structure and function. Topical applications of H1r and H2r antagonists enhanced epidermal differentiation, the latter at both the mRNA and protein levels, which could reflect the ability of these agents to mobilize intracellular calcium (Koizumi and Ohkawara, 1999). Enhanced differentiation translated further into a significant increase in the thickness of cornified envelopes, which should yield more robust corneocytes, also a Ca++-dependent process (Kim and Bae, 1998, Nemes and Steinert, 1999). The converse certainly proves this point -- effete cornified envelopes occur in several inherited disorders of cornification, including loss-of-function mutations in transglutaminase 1-deficient (lamellar) ichthyosis [rev. in (Schmuth, et al., 2007)], that display subnormal barrier function. Thus, the more robust corneocytes in topical H1/H2r-antagonist-treated skin likely contribute to enhanced barrier function.
We also show that topical antihistamines enhance barrier function by stimulating the synthesis and secretion of epidermal lipids. Multiple steps in the initial synthesis, later modification, and subsequent secretion of epidermal lipids were stimulated by topical applications of the H1r and/or H2r antagonists. Pertinently, hepatic lipid synthesis is similarly enhanced in both H1r and H2r knockout mice (Wang, et al., 2010). Yet, there were subtle differences in the effects of H1r and H2r antagonists on these metabolic pathways in normal epidermis. While both the H1r and H2r antagonists stimulate epidermal lipid synthesis, the H2r antagonists more-potently stimulate lamellar body production, which parallel enhancement of ABCA12 expression after H2r (but not H1r) antagonist applications. While the H1r antagonist displayed a lesser impact on organelle production (and ABCA12 expression), it instead appeared to accelerate lamellar body secretion. Thus, in addition to profound effects on epidermal differentiation, H1/2r antagonists strongly stimulate epidermal lipid synthesis, metabolism and secretion.
Based upon the putative link between abnormalities in barrier function and downstream inflammation, we reasoned that topical antihistamines could reduce inflammation in inflammatory dermatosis, at least in part by improving barrier function, as we showed previously with activators of the liposensor subclass of nuclear hormone receptors (i.e., PPARα, γ, β/δ and LXR). These agents not only improve barrier function in normal skin (Man, et al., 2006, Schmuth, et al., 2008), but also reduce inflammation in diverse inflammatory dermatosis models that may or may not be characterized by a barrier abnormality (Komuves, et al., 2000, Sheu, et al., 2002, Fowler, et al., 2003). Indeed, our results strongly suggest that the benefits of the topical H1/2r antagonists extend beyond their impact on barrier function, because they also reduced inflammation in two models, where barrier function remained normal (i.e., AICD and AACD). Thus, the topical H1/2r antagonists exhibit potent anti-inflammatory activity that could operate independently of, or in parallel to improved barrier function. In contrast, the SACD and AD models display progressively more-severe barrier abnormalities [(Man, et al., 2008, Hatano, et al., 2009, Hatano, et al., 2010) and these results]. Since both the H1r and H2r antagonists improve barrier function in both of these models, it is tempting to argue that this result reflects the impact of the antagonists on barrier function. The H1r antagonist, though highly anti-inflammatory, did not significantly improve barrier function in the AD model. Hence, it is not possible to discriminate which of these two mechanisms (anti-inflammatory vs. barrier enhancement) predominates in reducing inflammation. Yet, even the anti-inflammatory benefits could reflect direct effects on the epidermis, because both H1r and H2r antagonists oppose production of multiple keratinocyte-derived cytokines (Shimizu, et al., 2004, Matsubara, et al., 2005, Kobayashi, et al., 2009), independent of their well-known ability to stabilize histamine production by mast cells (Levi-Schaffer and Eliashar, 2009). Moreover, anti-inflammatory benefits can accrue with improved barrier function via a reduction in the barrier-initiated ‘cytokine cascade’ (Elias, et al., 2008a, Elias and Steinhoff, 2008). Pertinently, topical H1/2r agonists instead aggravated inflammation, perhaps by direct pro-inflammatory effects, or by further compromising barrier function, as they do after topical applications to normal skin [(Ashida, et al., 2001) and these studies].
Not only filaggrin-deficient atopic dermatitis (Sandilands, et al., 2009), but also all of the inherited ichthyoses studied to date (Schmuth, et al., 2007, Elias, et al., 2008b, Elias, et al., 2010), and most recently even psoriasis (Sun, et al., 2006, Tschachler, 2007, Chen, et al., 2009, Strange, et al., 2010), appear to be provoked by primary genetic alterations that compromise epidermal structure and function. Since these dermatoses are often driven or accompanied by prominent barrier abnormalities, not surprisingly, recent studies show that a variety of ‘barrier repair’ strategies comprise effective (and inherently safer) therapy for these disorders (Elias and Wakefield, 2011). The topical H1/2r antagonists, if they prove equally effective when deployed topically for their human disease counterparts, could be added to this list. Nonetheless, it now seems reasonable to propose that H1r and H2r antagonists could be deployed topically to treat a broad range of inflammatory dermatoses.
(Please read supplemental information for further details of Materials and Methods)
Female albino hairless (Skh1) mice, aged six-eight weeks, were from Charles River Laboratories (Wilmington, MA). Mast cell deficient mice (MCDM, KitW/KitW-v double heterozygous mice) and age- and gender-matched wild-type littermates (WBB6F1) were from Jackson Labs (Bar Harbor, ME). Ethanol and propylene glycol were from Fisher Scientific (Fairlane, NJ); diphenhydramine chlorhydrate and cimetidine were from Sigma (St Louis, MO), and affinity-purified, rabbit anti-mouse filaggrin, involucrin, and loricrin antibodies were from BabCo (Richmond, CA). Secondary biotinylated, goat anti-rabbit IgG and ABC-peroxidase kit were from Vector laboratories (Burlingame, CA). Anti-proliferating cell nuclear antigen antibody (PCNA, Ki-67) was from CalTag Laboratories (Burlingame, CA).
Animal procedures were approved and performed in accordance with guidelines of the Animal Studies Subcommittee (IACUC), San Francisco VA Medical Center. Mice were maintained in temperature- and humidity-controlled rooms, and given standard laboratory food and tap water ad libitum. Barrier disruption on hairless mice was achieved by repeated tape-stripping until 10 fold increase in transepidermal water loss. Mice were treated topically on one or both flanks with 5% diphenhydramine or 5% cimetidine or vehicle alone (propylene glycol:ethanol:water = 1:2:2, volume) twice-daily for four days. Changes in transepidermal water loss (TEWL), measured with an electrolytic water analyzer (Meeco, Warrington, PA), were measured 0, 2 and 4 hrs after sequential tape stripping, resulting in a 10-fold increase in TEWL, and percent barrier recovery rates was calculated (Man, et al., 1993, Man, et al., 2006, Man, et al., 2008). SC hydration was measured as changes in electrical capacitance, and surface pH with a flat surface electrode (Ibid.). For studies in MCDM, additional groups of WBB6F1 mice, treated with vehicle, served as controls.
Skin biopsies were taken from normal, 30 min, 3 hr and 6 hrs after barrier disruption. Mast cell infiltrates in the dermis were identified with 1% toluidine blue staining of 5 um paraffin sections. Pictures were taken at 20X with a Leica DM400B digital microscope, equipped with LAS v4.0 software. The density of mast cells was determined on every 25 cm2 area at regions between basement membrane and 5 cm below basement membrane in printed micrographs.
Data are expressed as the means ± SEM. Unpaired two-tailed student t test with Welch’s correction was used to determine significant differences when two groups were compared, and a one-way ANOVA with a post-Tukey Test or Dunnett post-correction was used to determine significant differences when three of more groups were compared.
FN3The authors state no conflict of interest.
These studies were supported by the San Francisco Veterans Affairs Medical Center, an NIH grant, AR019098, a grant from ISDIN, Ltd. (Barcelona, Spain), and an Austrian Science Fund grant T545-B19. Ms. Joan Wakefield provided superb editorial assistance. These contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIAMS or NIH.
|AACD||acute allergic contact dermatitis|
|AICD||acute irritant contact dermatitis|
|MCDM||mast cell deficient mice|
|rt(Q)-PCR||real time quantitative PCR|
|SACD||subacute allergic contact dermatitis|
|TEWL||transepidermal water loss|
|Ashida Y,Denda M,Hirao T. Year: 2001Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environmentJ Invest Dermatol116261511180002|
|Baumer W,Stahl J,Sander K,et al. Year: 2011Lack of preventing effect of systemically and topically administered histamine H(1) or H(4) receptor antagonists in a dog model of acute atopic dermatitisExp Dermatol205778121521369|
|Belsito DV,Kerdel FA,Potozkin J,et al. Year: 1990Cimetidine-induced augmentation of allergic contact hypersensitivity reactions in miceJ Invest Dermatol9444152313115|
|Buddenkotte J,Maurer M,Steinhoff M. Year: 2010Histamine and antihistamines in atopic dermatitisAdv Exp Med Biol7097380|
|Chen H,Toh TK,Szeverenyi I,et al. Year: 2009Association of skin barrier genes within the PSORS4 locus is enriched in Singaporean Chinese with early-onset psoriasisJ Invest Dermatol1296061418787534|
|Denda M. Year: 2002New strategies to improve skin barrier homeostasisAdv Drug Deliv Rev54Suppl 1S1233012460719|
|Denda M,Nakatani M,Ikeyama K,et al. Year: 2007Epidermal keratinocytes as the forefront of the sensory systemExp Dermatol161576117286806|
|Diepgen TL. Year: 2002Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 monthsPediatr Allergy Immunol132788612390444|
|Elias P,Williams M,Crumrine D,et al. Year: 2010Ichthyoses - clinical, biochemical, pathogenic, and diagnostic assessment39BaselS. Kargar AG144|
|Elias P,Wood L,Feingold K. Year: 1997Relationship of the epidermal permeability barrier to irritant contact dermatitisImmunol Allergy Clin North America17417430|
|Elias PM. Elias PM,Feingold KRYear: 2006The epidermal permeability barrier: from Saran Wrap to biosensorSkin BarrierNew YorkTaylor & Francis2531|
|Elias PM. Year: 2010Therapeutic implications of a barrier-based pathogenesis of atopic dermatitisAnn Dermatol222455420711259|
|Elias PM,Feingold KR. Year: 2001Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implicationsArch Dermatol13710798111493102|
|Elias PM,Hatano Y,Williams ML. Year: 2008aBasis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanismsJ Allergy Clin Immunol12113374318329087|
|Elias PM,Menon GK. Year: 1991Structural and lipid biochemical correlates of the epidermal permeability barrierAdv Lipid Res241261763710|
|Elias PM,Schmuth M. Year: 2009Abnormal skin barrier in the etiopathogenesis of atopic dermatitisCurr Opin Allergy Clin Immunol94374619550302|
|Elias PM,Steinhoff M. Year: 2008“Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitisJ Invest Dermatol12810677018408746|
|Elias PM,Wakefield JS. Year: 2011Therapeutic implications of a barrier-based pathogenesis of atopic dermatitisClin Rev Allergy Immunol412829521174234|
|Elias PM,Williams ML,Holleran WM,et al. Year: 2008bPathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolismJ Lipid Res4969771418245815|
|Elias PM,Wood LC,Feingold KR. Year: 1999Epidermal pathogenesis of inflammatory dermatosesAm J Contact Dermat101192610444104|
|Endo Y,Kikuchi T,Takeda Y,et al. Year: 1992GM-CSF and G-CSF stimulate the synthesis of histamine and putrescine in the hematopoietic organs in vivoImmunol Lett339131385320|
|Endo Y,Nakamura M,Nitta Y,et al. Year: 1995Effects of macrophage depletion on the induction of histidine decarboxylase by lipopolysaccharide, interleukin 1 and tumour necrosis factorBr J Pharmacol114187937712016|
|Eschler DC,Klein PA. Year: 2010An evidence-based review of the efficacy of topical antihistamines in the relief of pruritusJ Drugs Dermatol9992720684150|
|Feingold KR. Year: 2007Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasisJ Lipid Res4825314617872588|
|Feingold KR. Year: 2009The outer frontier: the importance of lipid metabolism in the skinJ Lipid Res50SupplS4172218980941|
|Fowler AJ,Sheu MY,Schmuth M,et al. Year: 2003Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine productionJ Invest Dermatol1202465512542530|
|Greaves MW. Year: 2005Antihistamines in dermatologySkin Pharmacol Physiol18220916015020|
|Gschwandtner M,Mommert S,Kother B,et al. Year: 2011The histamine H4 receptor is highly expressed on plasmacytoid dendritic cells in psoriasis and histamine regulates their cytokine production and migrationJ Invest Dermatol13116687621614010|
|Gunathilake R,Schmuth M,Scharschmidt TC,et al. Year: 2010Epidermal barrier dysfunction in non-atopic HIV: evidence for an “inside-to-outside” pathogenesisJ Invest Dermatol1301185819924137|
|Hatano Y,Man MQ,Uchida Y,et al. Year: 2010Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activatorsJ Allergy Clin Immunol1251609e1519818482|
|Hatano Y,Man MQ,Uchida Y,et al. Year: 2009Maintenance of an acidic stratum corneum prevents emergence of murine atopic dermatitisJ Invest Dermatol12918243519177139|
|Hill SJ,Ganellin CR,Timmerman H,et al. Year: 1997International Union of Pharmacology. XIII. Classification of histamine receptorsPharmacol Rev49253789311023|
|Irvine AD,McLean WH,Leung DY. Year: 2011Filaggrin mutations associated with skin and allergic diseasesN Engl J Med36513152721991953|
|Janssens AS,Heide R,den Hollander JC,et al. Year: 2005Mast cell distribution in normal adult skinJ Clin Pathol58285915735162|
|Kawashima M,Tango T,Noguchi T,et al. Year: 2003Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group studyBr J Dermatol14812122112828751|
|Kim SY,Bae CD. Year: 1998Calpain inhibitors reduce the cornified cell envelope formation by inhibiting proteolytic processing of transglutaminase 1Exp Mol Med30257629894158|
|Klein PA,Clark RA. Year: 1999An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitisArch Dermatol1351522510606058|
|Kobayashi M,Kabashima K,Nakamura M,et al. Year: 2009Downmodulatory effects of the antihistaminic drug bepotastine on cytokine/chemokine production and CD54 expression in human keratinocytesSkin Pharmacol Physiol2245819088500|
|Koizumi H,Ohkawara A. Year: 1999H2 histamine receptor-mediated increase in intracellular Ca2+ in cultured human keratinocytesJ Dermatol Sci211273210511481|
|Komuves LG,Hanley K,Man MQ,et al. Year: 2000Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARalpha activators restores tissue homeostasisJ Invest Dermatol115361710951269|
|Levi-Schaffer F,Eliashar R. Year: 2009Mast cell stabilizing properties of antihistaminesJ Invest Dermatol12925495119826448|
|Man MQ,Choi EH,Schmuth M,et al. Year: 2006Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processingJ Invest Dermatol1263869216374473|
|Man MQ,Feingold KR,Elias PM. Year: 1993Exogenous lipids influence permeability barrier recovery in acetone-treated murine skinArch Dermatol129728388507075|
|Man MQ,Hatano Y,Lee SH,et al. Year: 2008Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challengesJ Invest Dermatol128798617671515|
|Matsubara M,Tamura T,Ohmori K,et al. Year: 2005Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+-dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascadesBiochem Pharmacol694334915652235|
|Nemes Z,Steinert PM. Year: 1999Bricks and mortar of the epidermal barrierExp Mol Med3151910231017|
|Nickoloff BJ,Naidu Y. Year: 1994Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skinJ Am Acad Dermatol30535467512582|
|Oda T,Morikawa N,Saito Y,et al. Year: 2000Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytesJ Biol Chem27536781610973974|
|Pavlinkova G,Yanagawa Y,Kikuchi K,et al. Year: 2003Effects of histamine on functional maturation of dendritic cellsImmunobiology2073152514575147|
|Sandilands A,Sutherland C,Irvine AD,et al. Year: 2009Filaggrin in the frontline: role in skin barrier function and diseaseJ Cell Sci12212859419386895|
|Schmuth M,Gruber R,PME,et al. Year: 2007Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disordersAdv Dermatol2323125618159904|
|Schmuth M,Jiang YJ,Dubrac S,et al. Year: 2008Thematic Review Series: Skin Lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biologyJ Lipid Res4949950918182682|
|Sheu MY,Fowler AJ,Kao J,et al. Year: 2002Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis modelsJ Invest Dermatol1189410111851881|
|Shimizu T,Nishihira J,Watanabe H,et al. Year: 2004Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor: its potential anti-inflammatory actionClin Exp Allergy34103914720269|
|Strange A,Capon F,Spencer CC,et al. Year: 2010A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1Nat Genet429859020953190|
|Sun C,Mathur P,Dupuis J,et al. Year: 2006Peptidoglycan recognition proteins Pglyrp3 and Pglyrp4 are encoded from the epidermal differentiation complex and are candidate genes for the Psors4 locus on chromosome 1q21Hum Genet1191132516362825|
|Travis ER,Wang YM,Michael DJ,et al. Year: 2000Differential quantal release of histamine and 5-hydroxytryptamine from mast cells of vesicular monoamine transporter 2 knockout miceProc Natl Acad Sci U S A97162710618388|
|Tschachler E. Year: 2007Psoriasis: the epidermal componentClin Dermatol255899518021897|
|Wang KY,Tanimoto A,Yamada S,et al. Year: 2010Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in miceAm J Pathol1777132320566747|
|Wood LC,Jackson SM,Elias PM,et al. Year: 1992Cutaneous barrier perturbation stimulates cytokine production in the epidermis of miceJ Clin Invest9048271644919|
|Yamaguchi K,Motegi K,Kurimoto M,et al. Year: 2000Induction of the activity of the histamine-forming enzyme, histidine decarboxylase, in mice by IL-18 and by IL-18 plus IL-12Inflamm Res49513911089902|
Keywords: Antihistamines, epidermal differentiation, epidermal barrier function, epidermal lipid synthesis, H1 receptor, H2 receptor, treatment (therapy).
Previous Document: Global epidemiology of psoriasis: a systematic review of incidence and prevalence.
Next Document: Caspase-14-Deficient Mice Are More Prone to the Development of Parakeratosis.